HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reaffirmed a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and increased the price target from $25 to $35.
December 05, 2023 | 7:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EyePoint Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., with a raised price target from $25 to $35, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential, which can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100